Allergen Immunotherapy for Atopic Dermatitis: Is There Room for Debate?

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 3, 2016, Pages 435-444

  Cox, Linda ^a   Calderon, Moises A ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOUSE DUST ALLERGEN; PLACEBO;

ALLERGEN IMMUNOTHERAPY; APPLICATION SITE REACTION; ASTHMA; ATOPIC DERMATITIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; LIP DISEASE; LONG TERM CARE; META ANALYSIS (TOPIC); MOUTH DISEASE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW (TOPIC); URTICARIA; DESENSITIZATION; IMMUNOLOGY; PROCEDURES;

DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS;

EID: 84959307938     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.12.018     Document Type: Review

References (41)

1. Schneider L., Tilles S., Lio P., Boguniewicz M., Beck L., LeBovidge J., et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013, 131:295-299.e1-27.
2. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(Suppl):S1-S55.
3. Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999, 318:593-596.
4. Compalati E., Rogkakou A., Passalacqua G., Canonica G.W. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol 2012, 12:427-433.
5. Leung D.Y., Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014, 134:769-779.
6. Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy 2009, 64:265-275.
7. Bae J.M., Choi Y.Y., Park C.O., Chung K.Y., Lee K.H. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013, 132:110-117.
8. Schmitt J., Langan S., Williams H.C. European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007, 120:1389-1398.
9. Schmitt J., Spuls P.I., Thomas K.S., Simpson E., Furue M., Deckert S., et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014, 134:800-807.
10. EASI Scoring System. Available from: Accessed August 23, 2015. http://www.nottingham.ac.uk/homeforeczema/documents/easi-user-guide-dec-2014-final.pdf.
11. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993, 186:23-31.
12. Nankervis H., Pynn E.V., Boyle R.J., Rushton L., Williams H.C., Hewson D.M., et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev 2015, 1:CD008426.
13. Roekevisch E., Spuls P.I., Kuester D., Limpens J., Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014, 133:429-438.
14. Portnoy J.M. Immunotherapy for asthma: unfavorable studies. Ann Allergy Asthma Immunol 2001, 87(Suppl 1):28-32.
15. European Medicines Agency. Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. Available from: Published November 20, 2008. Accessed June 3, 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf.
16. Summary Basis for Regulatory Action Template. Available from: Accessed September 6, 2015. http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM393021.pdf.
17. Canonica G.W., Baena-Cagnani C.E., Bousquet J., Bousquet P.J., Lockey R.F., Malling H.J., et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007, 62:317-324.
18. GRASTEK® (Timothy Grass Pollen Allergen Extract). Available from: Accessed December 14, 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM393184.pdf.
19. RAGWITEKTM (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use Prescribing Information. Available from: Accessed December 26, 2014. http://www.merck.com/product/usa/pi_circulars/r/ragwitek/ragwitek_pi.pdf.
20. Bussmann C., Bockenhoff A., Henke H., Werfel T., Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?. J Allergy Clin Immunol 2006, 118:1292-1298.
21. Warner J.O., Price J.F., Soothill J.F., Hey E.N. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978, 2:912-915.
22. Glover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992, 22:440-446.
23. Kaufman H.S., Roth H.L. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy 1974, 32:321-330.
24. Silny W., Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis-results of double blind placebo controlled study. Pol Merkur Lekarski 2006, 21:558-565.
25. Werfel T., Breuer K., Rueff F., Przybilla B., Worm M., Grewe M., et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006, 61:202-205.
26. Pajno G.B., Caminiti L., Vita D., Barberio G., Salzano G., Lombardo F., et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007, 120:164-170.
27. Shi H.W.X., Ren H., Zhuang Y. Effect analysis of the dust mite allergen specific immunotherapy of chronic eczema. Chin J Derm Venereol 2010, 24:424-426.
28. Novak N., Bieber T., Hoffmann M., Folster-Holst R., Homey B., Werfel T., et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012, 130:925-931.e924.
29. Leroy B.P., Boden G., Lachapelle J.M., Jacquemin M.G., Saint-Remy J.M. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. J Am Acad Dermatol 1993, 28(Pt 1):232-239.
30. Galli E., Chini L., Nardi S., Benincori N., Panei P., Fraioli G., et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 1994, 22:18-22.
31. Gendelman S.R., Lang D.M. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Ann Allergy Asthma Immunol 2013, 111:555-561.
32. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982, 107:597-602.
33. Caraballo J.M.S., Villa R.C. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial. ISRN Allergy 2012, 2012:183983.
34. Gendelman S.R., Lang D.M. Sublingual immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Curr Allergy Asthma Rep 2015, 15:498.
35. Epstein T.G., Liss G.M., Murphy-Berendts K., Bernstein D.I. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2014, 2:161-167.e163.
36. Amin H.S., Liss G.M., Bernstein D.I. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006, 117:169-175.
37. Wyrzykowska N., Czarnecka-Operacz M., Adamski Z. Long-term efficacy of allergen specific immunotherapy in atopic dermatitis patients in relation to quality of life. Eur Ann Allergy Clin Immunol 2015, 47:5-9.
38. Meadows A., Kaambwa B., Novielli N., Huissoon A., Fry-Smith A., Meads C., et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013, 17:1-322. vi, xi-xiv.
39. Hankin C.S., Cox L. Allergy immunotherapy: what is the evidence for cost saving?. Curr Opin Allergy Clin Immunol 2014, 14:363-370.
40. Hankin C.S., Cox L., Bronstone A., Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 2013, 131:1084-1091.
41. National Guideline Clearinghouse Inclusion Criteria. Available from: Accessed September 6, 2015. http://www.guideline.gov/about/inclusion-criteria.aspx.